Sorafenib

CHEMBL1336 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

464.8 g/mol

LogP

4.1

Phase

4

This multi-targeted oral kinase inhibitor blocks several proteins that cancer cells use to grow new blood vessels and divide, effectively cutting off tumor blood supply and directly slowing cancer cell proliferation. It is approved for liver, kidney, and thyroid cancers and is studied in bladder and breast cancers.

Молекулярная масса

464,8000 g/mol

LogP

4,10

TPSA

92,40 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Type 2 Diabetes Hypertension Breast Cancer Hepatitis C Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1

InChI

InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

Molecular Formula

C21H16ClF3N4O3

HBD / HBA

3 / 7

Вращаемые Связи

5

Тяжёлые Атомы

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This multi-targeted oral kinase inhibitor blocks several proteins that cancer cells use to grow new blood vessels and divide, effectively cutting off tumor blood supply and directly slowing cancer cell proliferation. It is approved for liver, kidney, and thyroid cancers and is studied in bladder and breast cancers.

Yes, Sorafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1336. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 216239. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Sorafenib на PillFYI

Структура

Краткие Данные

Формула: C21H16ClF3N4O3
Синонимы: 2

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.